Antiretroviral Drug Switches in an Integrated TB and HIV Treatment Trial Anushka Naidoo, Kogieleum Naidoo, Tanuja Gengiah, Nesri Padayatchi, Aarthi Singh,

Slides:

Advertisements

Similar presentations

Indicators for monitoring ARV treatment outcomes.

Advertisements

Building Global HIV/AIDS Clinical Pharmacology Research Capacity HIV and TB: Capacity Challenges to the use of Current Drugs and Developing New Drugs Kimberly.

High Rates of Tuberculosis in Patients Accessing HAART in Rural South Africa – Implications for HIV and TB Treatment Programs Kogieleum Naidoo on behalf.

The new guidelines Dr Francois Venter Reproductive Health and HIV Research Unit University of the Witwatersrand Feb 2010.

Switch to EVG/c/FTC/TDF  STRATEGY-PI Study  STRATEGY-NNRTI Study.

A case series of ART-associated gynaecomastia reported to the National HIV & TB Healthcare Workers (HCW) hotline Christine Njuguna. Division of Clinical.

TMC125 Safety and Tolerability: 24-week Results of the Pooled DUET-1 and -2 Trials R Haubrich, M Schechter, S Walmsley, M Peeters, M Janssens, G De Smedt.

Adverse events in an integrated, home-based treatment program for MDR-TB & HIV in Tugela Ferry, South Africa JCM Brust*, NS Shah, TL van der Merwe, S Bamber,

Programme Case Studies

CAPRISA is the UNAIDS Collaborating Centre for HIV Research and Policy Impact of conditional cash incentives on HSV-2 and HIV in rural high school students.

Results of the CARINEMO ANRS randomized trial comparing the efficacy and safety of nevirapine vs efavirenz for treatment of HIV-TB co-infected patients.

PREVALENCE OF ANAEMIA IN WOMEN AT SCREENING AND FOLLOW-UP IN A MICROBICIDE PHASE III TRIAL Hasinah Asmal, Dinesh Singh, Gita Ramjee HIV Prevention Research.

Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother to Child Transmission of HIV-1 in Thailand NEJM July 15, 2004 Lallemant et.

HIV and AIDS Data Hub for Asia-Pacific Review in slides Treatment Last updated: December 2014.

Max O’Donnell, Nesri Padayatchi, Iqubal Master, Garth Osburn, Robert Horsburgh Treatment of Extensively Drug Resistant Tuberculosis Among Patients with.

BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.

Switch to ATV/r + 3TC  SALT Study. ATV/r 300/100 mg qd + 2 NRTI (investigator-selected) N = 143 ATV/r 300/100 mg + 3TC 300 mg qd  Design Randomisation*

When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.

Dr Kogie Naidoo Presented at the

WHO - PSM 14/7/2005 Principles for selection of medicines Dr Mary R. Couper Quality Assurance and Safety of Medicines WHO.

BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.

EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.

Bridging the gap between research, MCC approval and public access to tenofovir gel Quarraisha Abdool Karim on behalf of the CAPRISA 008 & CAPRISA 009 teams.

The Timing of ART initiation in TB HIV co-infected patients: Impact on IRIS severity 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention 20.

ALLY-2  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, in treatment-naïve genotype 1 treated for 12 weeks DCV + SOF 400 mg QD DCV + SOF.

Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.

Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Major Changes to the HHS Adult and Adolescent HIV Treatment Guidelines: April 2015 Brian R. Wood, MD.

Long-Term Comparison of Nevirapine Versus Efavirenz When Combined with Other Antiretroviral Drugs in HIV-1 Positive Antiretroviral-Naïve Persons- The NNRTI.

OUTCOME OF STAVUDINE INDUCED PERIPHERAL NEUROPATHY IN HIV-1 POSITIVE PATIENTS SWITCHED OR SUBSTITUTED TO A NON-STAVUDINE- BASED REGIMEN Dr P Gorejena-Chidawanyika.

Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.

Integration of TB and HIV Care Across Two Time Periods in Three (sub) Districts in South Africa J Sumitani 1,2, S Jed 1,2, S Galagan 2, J Gilvydis 1,2,

Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:

POWER 3 Study Confirms Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Patients Slideset on: Molina JM, Cohen C, Katlama C, et al.

Rare Cases of Hypokalemia Associated With Tenofovir Use Slideset on: Cirino CM, Kan VL. Hypokalemia in HIV patients on tenofovir. AIDS. 2006;20:

ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.

First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.

EPZICOM ® Virologic Response in ART-Naïve Patients with Baseline Viral Loads Above and Below 100,000c/mL Using the A5202 Endpoint K. Pappa, J. Hernandez,

Genotype-directed dosing for Efavirenz

Sashindran V K, Sashwat S, Kumar Suman,

I have no conflicts of interest to declare

ADVERSE OUTCOMES OF TREATING HIV-TB

Acceptability of early HIV treatment among South Africa women N Garrett, E Norman, V Asari, N Naicker, N Majola, K Leask, Q Abdool Karim and SS Abdool.

Dolutegravir plus Rilpivirine as Maintenance Dual Therapy SWORD-1 and SWORD- 2: Design

The Ethiopian TB HAART study: Find out the timing for ART when CD4< 200cells/µL Anything new? Wondwossen Amogne, Abiy H/ wold, Getent Yimer,

undetectable (undetectable-6.25)

Daniel Meressa, M.D. Global Health Committee St. Peter’s Hospital

Factors affecting virological failure in patients receiving antiretroviral therapy: a prospective HIV Clinical cohort in rural Uganda. Patrick Kazooba1,

Tolerability of Isoniazid Preventive Therapy (IPT) in an HIV infected cohort

CAPRISA Advanced Clinical Care Presented by: Nesri Padayatchi

Switch RPV-TDF-FTC from NVP-Based Regimen NEAR-Rwanda Trial

Cross-sectional assessment of patient outcomes using a systematic file review process: Results from 12,987 patient files Ambereen Jaffer, Gesine Meyer-Rath,

Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study

Dr Dawood Quiz questions.

Poster P200 18th Annual Conference of the British HIV Association (BHIVA), 18 – 20th April 2012, Birmingham, UK An analysis of the reasons for switching.

Metastatic Renal Cell Carcinoma

African perspective on ethical guidelines Salim S Abdool Karim

Phase 3 Treatment Naïve HIV Coinfection

Tolerability of Isoniazid Preventive therapy Among HIV infected Cohort in Nigeria Folajinmi Oluwasina Strategic Information Unit AIDS Healthcare Foundation,

MAGELLAN-3 Study: GLE/PIB + SOF + RBV in patients who failed GLE/PIB

Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens.

Indian Scenario HIV Situation TB Situation

ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: PROGRESS & CHALLENGES IN SOUTH AFRICA YOGAN PILLAY DEPARTMENT OF HEALTH, SOUTH AFRICA IAS, 2014.

Switch to LPV/r monotherapy

ARV-trial.com Switch to ATV/r + RAL HARNESS Study 1.

Background. Long-Term B/F/TAF Switch Efficacy in Patients with Archived Pre-Existing Resistance.

Sequencing cohorts Open-label Design W8 W12 ≥ 18 years

INTRODUCTION OBJECTIVES METHODS RESULTS DISCUSSION

The IAS TB/HIV Research Prizes are awarded to:

Presentation transcript:

Antiretroviral Drug Switches in an Integrated TB and HIV Treatment Trial Anushka Naidoo, Kogieleum Naidoo, Tanuja Gengiah, Nesri Padayatchi, Aarthi Singh, Munira Khan, Shiela Bamber, Gonasagrie Nair, Nonhlanhla Yende, Salim Abdool Karim, on behalf of the SAPiT study team.

Overview Background Challenges of concomitant treatment of TB/HIV coinfection include drug-drug interactions and overlapping toxicities Study Design Retrospective analysis of 561 TB/HIV co-infected patients in the SAPiT trial initiated onto ART Objective Investigation of rates and reasons for switching of first line ART drugs in TB/HIV co-treatment.

Results Summary of Single Drug Switches: N=13 Initial DrugReason for SwitchNumber of switches Median Time to Switch* (months) Months to Switch per AE* Didanosine (ddI)Peripheral Neuropathy36 (4-11)4 (1-11) N=6Hyperlactaemia Pancreatitis1 8 Liver Abnormalities1 EfavirenzCNS/Neuropsychiatric35 (2-11)4 (0.5-6) N=4Pregnancy1 15 Zidovudine (AZT) Anaemia1 5 (2-8) 8 2 N=2Hyperlactaemia1 Nevirapine N=1 Hypersensitivity Rash (with Grade 3 ALT) 188 Changes to Second Line Regimens N=22 EFV/3TC/ddIVirological Failure2211 (9-12) * From ART initiation

Conclusion 6% of cohort switched from first line drugs –1.8% due to toxicity or contra-indication –4.2% due to virological failure Baseline peripheral neuropathy experienced 17 fold increased risk for single drug switches Low overall incidence of additive toxicities Low overall virological failure

Acknowledgements We thank, the individuals who guided, and supported the design and conduct of the trial, the University of KwaZulu-Natal Biomedical Research Ethics Committee and the South African Medicines Control Council for their oversight of the trial as well as participants, sponsors and CAPRISA eThekweni Treatment Team